Toronto, Ontario (FSCwire) - Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC Pink®), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it will present at the Biotechnology Industry Organization (“BIO”) Conference on Thursday, June 18, 2015 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.

The Company’s presentation by Roger Dumoulin-White, President & CEO is scheduled to begin at 10:30 am ET.

About BIO Exhibition:

The world’s largest biotechnology gathering, the BIO exhibition allows exhibitors to reach high-level executives and influential decision makers who come to BIO to discover new players in the industry, form partnerships and evaluate emerging technologies.

The 2015 BIO exhibition will feature more than 1,700 exhibitors and approximately 160,000 square feet. The exhibition also includes 60+ state, regional and country pavilions who in turn host many companies from their regions. 

About Theralase Technologies Inc.

Theralase Technologies Inc. (“Theralase®”) (TSXV: TLT) (TLTFF: OTC Pink®) in its Therapeutic Laser Technology Division designs, manufactures and markets patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy Division researches and develops specially designed molecules called Photo Dynamic Compounds, which are able to localize to cancer cells and then when laser light activated, effectively destroy them.

Additional information is available at www.theralase.com and www.sedar.com .

Theralase Technologies Inc. was recognized as a TSX Venture 50® company in 2015. TSX Venture 50 is a trademark of TSX Inc. and is used under license.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

Roger Dumoulin-White                                                                                

President & CEO, Theralase Technologies Inc.                    

1.866.THE.LASE (843-5273) ext. 225                                         

416.699.LASE (5273) ext. 225                                                      

rwhite@theralase.com                                                                                

www.theralase.com

Maximum News Dissemination by FSCwire. http://www.fscwire.com

Copyright © 2015 Filing Services Canada Inc.